

The Warfarin/Aspirin Study in Heart failure

Submission date 23/01/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 23/01/2004	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 22/02/2008	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof John Cleland

Contact details

Castle Hill Hospital
University of Hull
Cottingham
Kingston upon Hull
United Kingdom
HU16 5UQ
+44 (0)1482 624 083/084
J.G.Cleland@hull.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

D15

Study information

Scientific Title

What is the most cost effective anti-thrombotic strategy to reduce mortality in heart failure? The WASH Study

Acronym

WASH Study

Study objectives

Heart failure is common and causes appreciable morbidity and mortality. It is associated with recurrent myocardial infarcts, strokes, and other thrombo-embolic events. For these reasons anti-thrombotic therapy using aspirin or warfarin is seen as normal clinical practice. However aspirin has a number of side-effects, and warfarin requires regular blood tests, increasing its cost and inconvenience for patients. Thus using these agents should be justified by clinical benefit. The aim of this study was to see if it would be possible to organise a trial of aspirin, warfarin, and no anti-thrombotic treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Heart disease

Interventions

1. Aspirin
2. Warfarin
3. No anti-thrombotic treatment

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

1. Deaths
2. Myocardial infarction
3. Stroke
4. Bleeding episodes
5. Dyspepsia
6. A number of laboratory tests

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/11/1995

Completion date

30/09/1998

Eligibility

Key inclusion criteria

Patients were being treated for heart failure, and had evidence of ventricular dysfunction to a defined level on echocardiography.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

279

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/11/1995

Date of final enrolment

30/09/1998

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Castle Hill Hospital

Kingston upon Hull

United Kingdom

HU16 5UQ

Sponsor information

Organisation

Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)

Sponsor details

The Department of Health

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

Sponsor type

Government

Website

<http://www.doh.gov.uk>

Funder(s)

Funder type

Government

Funder Name

NHS Cardiovascular Disease and Stroke National Research and Development Programme (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/07/2004		Yes	No